<div id="readability-page-1" class="page"><h3>Easter Sale - 70% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has issued an update. CARsgen Therapeutics Holdings Limited has convened its annual general meeting for 22 May 2026 in Shanghai, where shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025 and the accompanying directors’ and auditor’s reports. The meeting will also consider re‑electing three executive directors, confirming Ernst &amp; Young as auditor with board‑determined fees, approving director remuneration, and granting the board a general mandate to issue additional shares and deal with treasury shares, which may enhance the company’s financial flexibility and capital‑raising capacity. The proposed share issuance mandate, structured in line with Hong Kong Listing Rules, would allow directors to allot, issue, sell, or transfer shares and grant related options or awards within defined limits and exceptions, such as rights issues, share schemes, and scrip dividends. These governance and capital measures, if approved, are designed to support CARsgen’s ongoing operational needs and strategic initiatives while maintaining shareholder oversight of key appointments and financial reporting. The most recent analyst rating on (HK:2171) stock is a Hold with a HK$19.00 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page. More about CARsgen Therapeutics Holdings Ltd. CARsgen Therapeutics Holdings Limited is a biotechnology company focused on developing innovative therapies, with its shares listed on the Hong Kong Stock Exchange under stock code 2171. The company operates through subsidiaries and is subject to Hong Kong listing rules and corporate governance requirements, reflecting its integration into the regional capital markets. Average Trading Volume: 3,943,165 Technical Sentiment Signal: Buy Current Market Cap: HK$10.3B Find detailed analytics on 2171 stock on TipRanks’ Stock Analysis page.</div>

02171

512290

588130

CARsgen Therapeutics Holdings Ltd. has scheduled its annual general meeting for May 22, 2026, in Shanghai. Shareholders will vote on adopting the audited financial statements for 2025, re-electing three executive directors, confirming Ernst & Young as auditor, approving director remuneration, and granting a mandate for share issuance. This mandate aims to enhance financial flexibility and support operational needs. The latest analyst rating for CARsgen's stock (HK:2171) is a Hold with a price target of HK$19.00.

Tip Ranks

CARSGEN-B

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

CARsgen Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority